STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic...
Read More Details
Finally We wish PressBee provided you with enough information of ( US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) )
Also on site :
- Tears and Shock: First Islander Sent Home on ‘Love Island USA’ Season 7
- A Gaza-bound aid boat carrying Greta Thunberg and other activists has been diverted to Israel
- 'Hamilton’ Original Cast Reunites at 2025 Tony Awards & Fans Are Saying the Same Thing